
Opinion|Videos|July 18, 2024
Safety Data of Oral JAK Inhibitors in Atopic Dermatitis
Author(s)Ruth Ann Vleugels, MD, MPH, MBA
An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Are there differences in safety data from clinical trials vs. real-world studies? What has been your clinical experience with abrocitinib and upadacitinib?
- Discuss your monitoring schedule for patients taking JAK inhibitors.
- How do you modify your monitoring protocol according to patient characteristics and preferences?
- How do you modify your monitoring protocol according to patient characteristics and preferences?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD
2
Biologic Selection in Severe Asthma: Biomarkers, Comorbidities, When to Switch
3
What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata
4
FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis
5



























































